 |
|
Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
Gi-Ae Kim, Joon Ho Moon, Won Kim
Clin Mol Hepatol. 2023;29(4):831-843. Published online 2023 Aug 25 DOI: https://doi.org/10.3350/cmh.2023.0277
|
|
Citations to this article as recorded by
 Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up
Hun Jee Choe, Joon Ho Moon, Won Kim, Bo Kyung Koo, Nam H. Cho
Metabolism.2024; 153: 155800. CrossRef Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease
Zobair M. Younossi, James M. Paik, Maria Stepanova, Janus Ong, Saleh Alqahtani, Linda Henry
Journal of Hepatology.2024; 80(5): 694. CrossRef From Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Steatotic Liver Disease: Out with the Old, in with the New
Iyiad Alabdul Razzak, Mazen Noureddin, Hirsh Trivedi
Journal of Clinical Medicine.2024; 13(3): 880. CrossRef Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation
Byeong Hyun Min, Shivani Devi, Goo Hyun Kwon, Haripriya Gupta, Jin-Ju Jeong, Satya Priya Sharma, Sung-Min Won, Ki-Kwang Oh, Sang Jun Yoon, Hee Jin Park, Jung A Eom, Min Kyo Jeong, Ji Ye Hyun, Nattan Stalin, Tae-Sik Park, Jieun Choi, Do Yup Lee, Sang Hak H
Gut Microbes.2024;[Epub] CrossRef Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
Yewan Park, Jooyi Jung, Seungbong Han, Gi‐Ae Kim
Alimentary Pharmacology & Therapeutics.2024;[Epub] CrossRef Metabolic dysfunction-associated steatotic liver disease: An opportunity for collaboration between cardiology and hepatology
Paolo Raggi, Jovana Milic, Marcella Manicardi, Felice Cinque, Mark G. Swain, Giada Sebastiani, Giovanni Guaraldi
Atherosclerosis.2024; 392: 117523. CrossRef Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression
Sumin Oh, Yang-Hyun Baek, Sungju Jung, Sumin Yoon, Byeonggeun Kang, Su-hyang Han, Gaeul Park, Je Yeong Ko, Sang-Young Han, Jin-Sook Jeong, Jin-Han Cho, Young-Hoon Roh, Sung-Wook Lee, Gi-Bok Choi, Yong Sun Lee, Won Kim, Rho Hyun Seong, Jong Hoon Park, Yeon
Clinical and Molecular Hepatology.2024; 30(2): 247. CrossRef Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study
Michihiro Iwaki, Hideki Fujii, Hideki Hayashi, Hidenori Toyoda, Satoshi Oeda, Hideyuki Hyogo, Miwa Kawanaka, Asahiro Morishita, Kensuke Munekage, Kazuhito Kawata, Tsubasa Tsutsumi, Koji Sawada, Tatsuji Maeshiro, Hiroshi Tobita, Yuichi Yoshida, Masafumi Na
Clinical and Molecular Hepatology.2024; 30(2): 225. CrossRef Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
Tsubasa Tsutsumi, Dan Nakano, Machiko Kawaguchi, Hirokazu Takahashi, Takumi Kawaguchi
Clinical and Molecular Hepatology.2024; 30(2): 266. CrossRef Immunopathogenesis of liver fibrosis in steatotic liver disease
Chaerin Woo, Won-Il Jeong
Clinical and Molecular Hepatology.2024; 30(2): 299. CrossRef Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD
Hiroyuki Suzuki, Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Takumi Kawaguchi
Clinical and Molecular Hepatology.2024; 30(2): 263. CrossRef Nonalcoholic fatty liver disease associated with obesity and type 2 diabetes and gut dysbiosis
T.M. Bentsa
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2024; 20(2): 120. CrossRef The clinician's view on the advantages and contradictions of the new nomenclature of steatotic liver disease: A review
Chavdar S. Pavlov, Daria A. Teplyuk, Leonid B. Lazebnik, Aleksandr S. Ametov, Evgeniia Yu. Pashkova, Sergey M. Sorokoletov, Yury P. Uspenskiy, Svetlana V. Turkina, Elizaveta V. Ponomarenko, Aleksandr S. Maslakov
Terapevticheskii arkhiv.2024; 96(4): 429. CrossRef Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, Marlene Chakhtoura, Michael A. Hill, Dimitri P. Mikhailidis, Christos S. Mantzoros, Ali Eid
Pharmacological Reviews.2024; 76(3): 454. CrossRef Prognostic Impact of Metabolic Syndrome and Steatotic Liver Disease in Hepatocellular Carcinoma Using Machine Learning Techniques
Sergio Gil-Rojas, Miguel Suárez, Pablo Martínez-Blanco, Ana M. Torres, Natalia Martínez-García, Pilar Blasco, Miguel Torralba, Jorge Mateo
Metabolites.2024; 14(6): 305. CrossRef Are transmembrane 6 superfamily member 2 gene polymorphisms associated with steatohepatitis after pancreaticoduodenectomy?
Tomotaka Mori, Eisuke Ozawa, Ryu Sasaki, Akane Shimakura, Kosuke Takahashi, Yoko Kido, Yasuko Kanda, Satoshi Matsuo, Kazuaki Tajima, Asami Beppu, Yasuhiko Nakao, Masanori Fukushima, Masafumi Haraguchi, Satoshi Miuma, Hisamitsu Miyaaki, Tomohiko Adachi, Su
JGH Open.2024;[Epub] CrossRef Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia
Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi
Clinical and Molecular Hepatology.2024; 30(3): 577. CrossRef Impacts of cardiometabolic risk factors and alcohol consumption on all-cause mortality among MASLD and its subgroups
Mengqi Li, Wenya Chen, You Deng, Wen Xie
Nutrition, Metabolism and Cardiovascular Diseases.2024; 34(9): 2085. CrossRef Interleukin-mediated therapies in liver diseases and comorbidity effects
Nouhoum Bouare, Jean Delwaide
World Journal of Hepatology.2024; 16(7): 980. CrossRef A New Korean Nomenclature for Steatotic Liver Disease
The Korean Journal of Gastroenterology.2024; 84(1): 1. CrossRef Impact of Physical Activity on Overall Survival and Liver Cirrhosis Incidence in Steatotic Liver Disease: Insights from a Large Cohort Study Using Inverse Probability of Treatment Weighting
Keungmo Yang, Beom Sun Chung, Tom Ryu
Nutrients.2024; 16(15): 2532. CrossRef Machine learning model reveals roles of interferon‑stimulated genes in sorafenib‑resistant liver cancer
Deok Seo, Ji Park, Hee Jung, Min Kang, Byung Kang, Dong Lee, Jae Lee, Seung Yoon, Jeong Jang, Jae Ahn, Pil Sung
Oncology Letters.2024;[Epub] CrossRef Role of Neutrophils in the Development of Steatotic Liver Disease
You-Jin Choi, Yeonsoo Kim, Seonghwan Hwang
Seminars in Liver Disease.2024;[Epub] CrossRef A New Korean Nomenclature for Steatotic Liver Disease
The Korean Journal of Medicine.2024; 99(4): 189. CrossRef Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies
Hao CHEN, Yang ZHOU, Haiping HAO, Jing XIONG
Chinese Journal of Natural Medicines.2024; 22(8): 724. CrossRef Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study
Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon, Hyung Ho Lee, Heejoo Park, Jian Lee, Youngsun Park, Byungyoon Yun, Jinsoo Chung
Cancers.2024; 16(18): 3161. CrossRef A New Korean Nomenclature for Steatotic Liver Disease
Gut and Liver.2024; 18(5): 924. CrossRef Serum isthmin-1 is a potential biomarker for metabolic dysfunction associated fatty liver disease in patients with metabolic syndrome and type 2 diabetes mellitus
Xiaohui Lei, HaiYan Chen, YuXin Xu, Zhuoran Yang, Lili Zhang, Cong Wang, Hu Du
BMJ Open Diabetes Research & Care.2024; 12(5): e004514. CrossRef Adding to the confusion in more than just the name
Jacob George
Clinical and Molecular Hepatology.2023; 29(4): 973. CrossRef From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials
Ming-Lun Yeh, Ming-Lung Yu
Clinical and Molecular Hepatology.2023; 29(4): 969. CrossRef Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study
Joon Ho Moon, Seogsong Jeong, Heejoon Jang, Bo Kyung Koo, Won Kim
eClinicalMedicine.2023; 65: 102292. CrossRef Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD
Shuhei Fukunaga, Michita Mukasa, Dan Nakano, Tsubasa Tsutsumi, Takumi Kawaguchi
Clinical and Molecular Hepatology.2023; 30(1): 121. CrossRef
|